Press Releases

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize CV-01 in the Republic of […]

Press Releases

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize CV-01 in the Republic of […]

Press Releases

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize CV-01 in the Republic of […]

Press Releases

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize CV-01 in the Republic of […]

Press Releases

KnowBe4 Sheds Light on the Alarming Trends of Human Trafficking Through Social Engineering in the UAE

DUBAI, UAE, Oct. 21, 2024 (GLOBE NEWSWIRE) — Human trafficking continues to be an issue in the UAE, particularly affecting foreign workers from Africa and South and Southeast Asia. Lured with false promises of high-paying jobs, victims arrive in the UAE only to have their passports confiscated and find themselves in forced labor or even […]

Press Releases

KnowBe4 Sheds Light on the Alarming Trends of Human Trafficking Through Social Engineering in the UAE

DUBAI, UAE, Oct. 21, 2024 (GLOBE NEWSWIRE) — Human trafficking continues to be an issue in the UAE, particularly affecting foreign workers from Africa and South and Southeast Asia. Lured with false promises of high-paying jobs, victims arrive in the UAE only to have their passports confiscated and find themselves in forced labor or even […]